.svg)
Products
.svg)
Protein-PCR™ for Neurological Diseases
Bring blood-based TBI and Alzheimer's biomarker testing to the qPCR systems you already own, deliver validated performance at an affordable cost and built to scale, empowering clinicians and researchers alike.
.svg)
Key Products
.svg)
Our Solutions
Powered by Protein-PCR™, detect Traumatic Brain Injury (TBI) and Alzheimer’s disease (AD) earlier on standard qPCR systems to inform care decisions sooner and track change over time.
Alzheimer's Disease Detection
Our AD blood biomarker kit quantifies four widely validated markers (Aβ40, Aβ42, pTau181, and pTau217) from standard blood samples at very low concentrations. Its ultra-sensitive performance supports early detection (reports of >97.5% PPA/NPA vs. Simoa®/ELISA) and the potential to identify risk 15–20 years before clinical symptoms in studied populations.
.svg)
.svg)
Traumatic Brain Injury Detection
Our TBI blood biomarker kit quantifies validated markers (GFAP, ALDOC, NGRN, BDNF, and ST2) from standard blood samples at very low concentrations, enabling early assessment, risk stratification, and ongoing monitoring after injury. In comparator studies with Simoa®/ELISA, the assay achieved >97.5% PPA/NPA, indicating strong agreement with established methods and supporting scalable, in-house use.
Future of Protein-PCR™
We aim to expand our Protein-PCR™ technology to address a broad range of applications, including Parkinson's disease, multiple sclerosis, other neurological diseases, various cancers, and other conditions that demand ultra-sensitive detection. AperionDx welcomes collaborations for companion diagnostic applications, and developing custom biomarker assays for use in drug development.
.svg)
How It Works
INSIDE PROTEIN-PCR™
A streamlined process that makes diagnostics faster, smarter and more reliable.
.webp)
.webp)
.webp)
Use Cases
Trusted Across Industries
From research to patient care, AperionDx empowers progress everywhere.
Research Labs
Accelerating scientific research and discovery with high sensitivity at a low cost with tools available in most labs.
HOSPITALS & CLINICS*
Supporting patient outcomes with fast and highly accurate disease diagnosis and monitoring.
*Upon completion of FDA review
*Upon completion of FDA review
.svg)
.svg)
.svg)
Biotech Companies
Empowering innovation in drug development by testing the most valid full-panel biomarkers.
Pharma & Drug
Enabling large-scale cohorts and clinical trials by quick and scalable biomarker testing.
.svg)
.svg)
.svg)
.svg)